BSE Live
Oct 24, 16:01Prev. Close
379.00
Open Price
371.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
| Balance Sheet of Trident Texofab (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 13.56 | 10.07 | 10.07 | 10.07 | 10.07 | |
| Total Share Capital | 13.56 | 10.07 | 10.07 | 10.07 | 10.07 | |
| Reserves and Surplus | 29.57 | 6.19 | 5.11 | 2.89 | 1.91 | |
| Total Reserves and Surplus | 29.57 | 6.19 | 5.11 | 2.89 | 1.91 | |
| Total Shareholders Funds | 47.24 | 16.26 | 15.18 | 12.96 | 11.98 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 7.43 | 17.74 | 18.58 | 20.27 | 19.19 | |
| Deferred Tax Liabilities [Net] | 0.54 | 1.11 | 1.38 | 0.97 | 0.68 | |
| Other Long Term Liabilities | 4.62 | 4.51 | 4.93 | 6.54 | 5.68 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 12.59 | 23.36 | 24.89 | 27.78 | 25.54 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 19.07 | 19.23 | 16.07 | 15.72 | 9.96 | |
| Trade Payables | 14.86 | 16.69 | 17.62 | 11.39 | 16.22 | |
| Other Current Liabilities | 3.30 | 3.71 | 1.63 | 1.32 | 3.17 | |
| Short Term Provisions | 3.53 | 2.65 | 1.91 | 1.82 | 0.91 | |
| Total Current Liabilities | 40.75 | 42.28 | 37.23 | 30.25 | 30.25 | |
| Total Capital And Liabilities | 100.58 | 81.90 | 77.31 | 70.99 | 67.77 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 20.09 | 21.73 | 23.33 | 21.71 | 14.21 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 3.62 | 8.89 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 20.09 | 21.73 | 23.33 | 25.33 | 23.11 | |
| Non-Current Investments | 1.89 | 3.74 | 3.64 | 2.06 | 2.48 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Other Non-Current Assets | 4.85 | 4.32 | 3.65 | 3.57 | 2.17 | |
| Total Non-Current Assets | 26.83 | 29.79 | 30.62 | 30.96 | 27.78 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 15.96 | 13.55 | 10.64 | 7.27 | 8.01 | |
| Trade Receivables | 40.71 | 36.67 | 33.87 | 30.85 | 30.28 | |
| Cash And Cash Equivalents | 3.16 | 0.16 | 0.06 | 0.04 | 0.03 | |
| Short Term Loans And Advances | 1.25 | 0.00 | 0.00 | 0.00 | 0.09 | |
| OtherCurrentAssets | 12.67 | 1.73 | 2.11 | 1.86 | 1.58 | |
| Total Current Assets | 73.74 | 52.10 | 46.69 | 40.03 | 40.00 | |
| Total Assets | 100.58 | 81.90 | 77.31 | 70.99 | 67.77 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 1.05 | 1.44 | 1.44 | 1.44 | 1.44 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 0.00 | 0.00 | 0.00 | 0.04 | 0.11 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | -- | -- | -- | -- | -- | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 8.20 | 8.20 | 8.20 | 8.20 | 8.20 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 1.89 | 3.74 | 3.64 | 2.06 | 2.48 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
26.08.2025
Trident Texofab Standalone June 2025 Net Sales at Rs 28.08 crore, up 9.2% Y-o-Y
19.06.2025
Trident Texofab Standalone March 2025 Net Sales at Rs 38.21 crore, up 26.63% Y-o-Y
04.02.2025
Trident Texofab Standalone December 2024 Net Sales at Rs 31.69 crore, up 37.72% Y-o-Y
21.10.2024
Trident Texofab Standalone September 2024 Net Sales at Rs 26.45 crore, up 13.99% Y-o-Y
26.08.2025
Trident Texofab Standalone June 2025 Net Sales at Rs 28.08 crore, up 9.2% Y-o-Y
19.06.2025
Trident Texofab Standalone March 2025 Net Sales at Rs 38.21 crore, up 26.63% Y-o-Y
04.02.2025
Trident Texofab Standalone December 2024 Net Sales at Rs 31.69 crore, up 37.72% Y-o-Y
21.10.2024
Trident Texofab Standalone September 2024 Net Sales at Rs 26.45 crore, up 13.99% Y-o-Y
05.04.2017
30.03.2017
29.03.2017
28.03.2017